Kazia Therapeutics: Closes $1.8M share purchase plan
- Biotech company Kazia Therapeutics (KZA) has closed its $1.8M share purchase plan
- Then the share purchase plan offered eligible shareholders the opportunity to purchase up to $30,000 worth of new shares
- Approximately 4.5M shares were issued to eligible shareholders at a price of 40 cents per share
- They are also expected to allocated on May 11 and begin trading on the ASX on May 12
- The money also raised will used to progress Kazia’s paxalisib clinical trial, complete analysis of its Cantrixil phase one study, and as working capital
- Kazia is up a slight 1.3 per cent on the market and shares are currently trading for 39 cents each
